Download Sample
Add to CartGlobal Drug Eluting Stents Market Growth, Share, Size, Trends and Forecast (2025 - 2031)
By Type;
Coronary Stenting and Peripheral Stenting.By Drug Coating;
Polymer-Based Coatings - Non - Biodegradable Polymers and Biodegradable Polymers, Polymer Free Coatings - Micro Porous Surface, Micro Structured Surface, Slotted Tubular Surface, and Nanoporous Surface.By Scaffold;
Cobalt-Chromium, Platinum-Chromium, Nitinol, and Others.By Application;
Coronary Artery Disease, and Peripheral Artery Disease.By End User;
Hospitals and Specialty Clinics.By Geography;
North America, Europe, Asia Pacific, Middle East and Africa, and Latin America - Report Timeline (2021 - 2031).Introduction
Global Drug Eluting Stents Market (USD Million), 2021 - 2031
In the year 2024, the Global Drug Eluting Stents Market was valued at USD 7,865.27 million. The size of this market is expected to increase to USD 12,997.98 million by the year 2031, while growing at a Compounded Annual Growth Rate (CAGR) of 7.4%.
The drug-eluting stents (DES) market represents a vital segment within the broader cardiovascular medical device industry, characterized by continuous innovation and significant global demand. DES are small, wire mesh tubes coated with medications that are inserted into narrowed arteries to help keep them open and improve blood flow. They have revolutionized the treatment of coronary artery disease (CAD), offering a minimally invasive alternative to traditional bypass surgery. DES are widely used in patients with CAD to prevent restenosis, a condition where the treated artery becomes narrowed again.
Technological advancements in biomaterials, coatings, and drug delivery systems have fueled the evolution of DES, enhancing their efficacy and safety profiles. Companies are investing heavily in research and development to improve DES performance, reduce complications, and expand their applications beyond CAD. Emerging markets, particularly in developing countries, present substantial growth opportunities for DES manufacturers due to increasing prevalence of cardiovascular diseases, rising healthcare expenditures, and improving healthcare infrastructure.
The trend towards personalized medicine is driving innovation in DES customization, tailoring stent designs and drug formulations to individual patient characteristics and disease profiles. This shift not only improves treatment outcomes but also reduces adverse events, leading to better patient care. Additionally, there's growing interest in leveraging DES technology to treat other vascular conditions such as peripheral artery disease (PAD) and neurovascular interventions. By diversifying into these adjacent therapies, DES manufacturers can tap into new markets and further expand their revenue streams.
Global Drug Eluting Stents Market Recent Developments
-
In June 2021, Abbott announced that its XIENCE stent product line received U.S. FDA approval and CE Mark certification in Europe for one-month Dual Antiplatelet Therapy (DAPT), marking the shortest blood thinning regimen for high bleeding risk patients in the U.S.
-
In January 2021, Boston Scientific Corporation received U.S. FDA approval for its Synergy Megatron Drug Eluting Stent System, specifically designed to treat large proximal vessels near the aorta.
Segment Analysis
The Global Drug Eluting Stents (DES) Market is segmented by Type, Drug Coating, Scaffold, Application, and End User, allowing for a deeper understanding of market dynamics across various dimensions.
By Type, the market is primarily divided into Coronary Stenting and Peripheral Stenting. Coronary stenting continues to dominate the market, driven by the high incidence of coronary artery disease (CAD), which necessitates procedures like angioplasty. Drug-eluting coronary stents are critical for preventing restenosis and ensuring better long-term outcomes for patients with CAD. However, Peripheral stenting is gaining momentum as the incidence of peripheral artery disease (PAD) rises, particularly in older populations and those with comorbidities such as diabetes. The increasing awareness of PAD and advancements in treatment options are expected to drive the growth of the peripheral stent segment in the future.
In terms of Drug Coating, the market is segmented into Polymer-Based Coatings and Polymer-Free Coatings. Within polymer-based coatings, there are Non-Biodegradable Polymers and Biodegradable Polymers, each offering different benefits related to the duration of drug release and the body’s ability to absorb or eliminate the material over time. Polymer-free coatings offer innovative solutions, with Micro Porous Surface, Micro Structured Surface, Slotted Tubular Surface, and Nanoporous Surface providing varied methods of drug delivery and improved performance. These technologies are gaining popularity due to their potential to reduce complications such as inflammation and thrombosis, while offering controlled drug release mechanisms.
By Scaffold, the market includes materials such as Cobalt-Chromium, Platinum-Chromium, Nitinol, and others. Cobalt-Chromium stents are widely used for coronary applications due to their strength and durability. Platinum-Chromium is preferred for its enhanced flexibility and imaging properties, while Nitinol, a nickel-titanium alloy, is favored for its superelasticity and ability to withstand repeated expansion and contraction. Each material has its advantages, which are influencing the selection of stents depending on patient-specific needs and procedural requirements. Application-wise, the Coronary Artery Disease segment holds a larger share, but Peripheral Artery Disease is expected to grow due to the increasing prevalence of lifestyle-related diseases and an aging population.
Finally, by End-User, the market is driven by Hospitals and Specialty Clinics, where most stent procedures take place. These settings are equipped with the latest medical technologies and have the expertise required for handling complex vascular procedures. The ongoing adoption of minimally invasive procedures and the improvement in procedural outcomes are further reinforcing the demand for drug-eluting stents in these environments.
Global Drug Eluting Stents Segment Analysis
In this report, the Global Drug Eluting Stents Market has been segmented by Type, Drug Coating, Scaffold, Application, End User, and Geography.
Global Drug Eluting Stents Market, Segmentation by Type
The Global Drug Eluting Stents Market has been segmented by Type into Coronary Stenting and Peripheral Stenting.
The Global Drug Eluting Stents (DES) Market is segmented by Type into Coronary Stenting and Peripheral Stenting. Coronary stenting dominates the market, as it is primarily used to treat coronary artery disease (CAD), which is one of the leading causes of heart attacks worldwide. Coronary stents are designed to restore blood flow to the heart by keeping the arteries open after angioplasty procedures. Drug-eluting coronary stents (DES) are coated with medications that help prevent restenosis (the re-narrowing of arteries) by inhibiting cell growth, thus offering long-term effectiveness and improving patient outcomes. The widespread prevalence of CAD, along with advances in DES technology, continues to drive the demand for coronary stents in hospitals and specialty clinics.
On the other hand, Peripheral stenting refers to the use of drug-eluting stents in the treatment of peripheral artery disease (PAD), which affects the arteries outside of the heart, particularly in the legs. While not as prevalent as coronary artery disease, PAD is becoming increasingly common due to the aging global population and rising rates of diabetes and smoking. Peripheral stents are designed to improve blood flow in the peripheral arteries and reduce symptoms such as pain and cramping in the legs, often improving the patient's quality of life. The growing awareness of PAD and the increasing demand for minimally invasive procedures have boosted the adoption of drug-eluting stents for peripheral applications.
Both coronary stenting and peripheral stenting contribute to the growth of the drug-eluting stents market, but coronary stenting holds a larger share due to the higher number of coronary artery procedures performed globally. However, the rising prevalence of peripheral artery disease is expected to propel the demand for drug-eluting peripheral stents in the coming years. This segmentation highlights the diverse applications of drug-eluting stents, addressing various vascular conditions and offering tailored treatments for both heart and peripheral artery diseases.
Global Drug Eluting Stents Market, Segmentation by Drug Coating
The Global Drug Eluting Stents Market has been segmented by Drug Coating into Polymer-Based Coatings - Non - Biodegradable Polymers and Biodegradable Polymers, Polymer Free Coatings - Micro Porous Surface, Micro Structured Surface, Slotted Tubular Surface, and Nanoporous Surface.
The dominance of polymer-based coatings in the drug eluting stent (DES) market is underscored by their well-established efficacy and versatility. These coatings, extensively studied and utilized in stent development, offer a reliable choice for manufacturers seeking controlled drug release and sustained delivery. By preventing restenosis and enhancing patient outcomes, polymer-based coatings have solidified their leading position in the market. For example, Abbott's XIENCE Skypoint stent, launched in June 2021, features a unique polymer coating designed to offer a shorter blood thinner course for high bleeding risk patients, highlighting the advancements driving the appeal of polymer-based coatings.
The polymer-free coating segment is poised to witness significant growth, with an anticipated highest compound annual growth rate (CAGR) during the forecast period. This growth is fueled by the increasing demand for polymer-free coatings in the DES market, driven by their potential to address long-term concerns associated with traditional polymer-based coatings. Polymer-free coatings have demonstrated promise in minimizing the risk of delayed healing and late adverse events, such as restenosis and thrombosis. Positive outcomes, as evidenced by studies like the one published in the Journal of the American College of Cardiology , which highlighted favorable results with reduced target lesion failure risk in patients with coronary artery disease, are encouraging healthcare providers to consider polymer-free drug eluting stents as a viable and promising option for their patients. Furthermore, ongoing advancements in materials science and surface engineering techniques are contributing to the development of innovative polymer-free coatings with enhanced biocompatibility and drug-delivery capabilities.
Global Drug Eluting Stents Market, Segmentation by Scaffold
The Global Drug Eluting Stents Market has been segmented by Scaffold into Cobalt-Chromium, Platinum-Chromium, Nitinol and Others.
The cobalt-chromium scaffold segment is one of the most widely used in the drug-eluting stents (DES) market, primarily due to its superior mechanical properties, including strength, radiopacity, and ease of fabrication. Cobalt-chromium alloys are well-regarded for their ability to provide the necessary structural support to the stent while allowing for thinner struts, which in turn improve the flexibility and deliverability of the device. These stents are often preferred for coronary artery disease (CAD) applications, where precise placement and long-term patency are critical. Additionally, cobalt-chromium stents tend to have a lower profile, making them suitable for use in small or tortuous arteries. The durability and performance of cobalt-chromium scaffolds have made them a mainstay in the DES market, especially in developed regions with advanced healthcare infrastructure.
Platinum-chromium stents represent an emerging segment in the drug-eluting stents market, offering distinct advantages in terms of both clinical performance and radiographic visibility. The platinum-chromium alloy provides enhanced radiopacity, which allows for better visualization during angioplasty procedures. This is particularly important for complex procedures where accurate placement of the stent is critical. Platinum-chromium stents also feature improved mechanical properties, such as higher strength and flexibility, compared to traditional cobalt-chromium stents. These benefits have driven their adoption, particularly in cases requiring precise stent placement, such as those involving small coronary arteries or complex lesions. While platinum-chromium stents are slightly more expensive than cobalt-chromium stents, their enhanced performance and better patient outcomes have made them increasingly popular among cardiologists, especially in developed markets.
Nitinol, a nickel-titanium alloy, is another important scaffold material in the drug-eluting stents market, primarily due to its unique properties of superelasticity and shape memory. Nitinol stents can expand more uniformly once deployed in the artery, reducing the risk of stent deformation and ensuring more consistent results. Nitinol’s ability to return to its original shape makes it particularly valuable in treating conditions where the artery might be subject to significant movement or stress, such as in peripheral artery disease (PAD) or in areas where there is a high risk of stent recoil. Additionally, nitinol stents are highly resistant to corrosion, making them suitable for long-term implantation. The "Others" category includes various alternative materials such as stainless steel and bioresorbable polymers, the latter of which is an emerging segment. Bioresorbable stents, which gradually dissolve over time after fulfilling their role of supporting the artery, are gaining interest due to their potential to eliminate long-term implant risks. While still a niche segment, bioresorbable scaffolds are considered a promising innovation for the future of drug-eluting stents, especially for patients who may not require a permanent stent.
Global Drug Eluting Stents Market, Segmentation by Application
The Global Drug Eluting Stents Market has been segmented by Application into Coronary Artery Disease and Peripheral Artery Disease.
The dominance of the coronary artery disease (CAD) segment in the drug eluting stent (DES) market is underpinned by the escalating prevalence of CAD globally, which poses a substantial cardiovascular concern. CAD is estimated to be responsible for approximately 610,000 deaths annually in the United States alone, making it the leading cause of mortality. Furthermore, on a global scale, CAD ranks as the third leading cause of mortality, contributing to around 17.8 million deaths annually. DES has emerged as a highly effective intervention for CAD, offering patients a minimally invasive and efficient solution to address the condition. Continuous advancements in drug eluting stent technology, exemplified by the successful commercial implantation and European launch of SINOMED's HT Supreme Drug Eluting Stent in August 2021, further bolster the segment's growth by delivering promising outcomes and fostering greater adoption of these devices.
The peripheral artery disease (PAD) segment is poised to witness robust growth, with an anticipated highest compound annual growth rate (CAGR) during the forecast period. This growth trajectory is attributed to the increasing prevalence of PAD on a global scale. The rising incidence of PAD, particularly among the aging population with risk factors like diabetes and obesity, has fueled significant demand for effective treatment solutions, driving the extensive utilization of drug eluting stents in managing PAD. As a result, the market for drug eluting stents is expected to witness substantial expansion in the peripheral artery disease segment, reflecting the growing clinical need and adoption of these devices in addressing vascular diseases beyond coronary artery disease.
Global Drug Eluting Stents Market, Segmentation by End User
The Global Drug Eluting Stents Market has been segmented by End User into Hospitals and Specialty Clinics.
The Global Drug Eluting Stents Market is primarily segmented by End User, which includes Hospitals and Specialty Clinics. Hospitals are the largest end-users of drug-eluting stents (DES), given their comprehensive infrastructure and ability to provide a wide range of medical procedures, including complex coronary artery interventions. Hospitals, particularly those with cardiac care units, are equipped with specialized teams and advanced technologies for performing procedures such as percutaneous coronary interventions (PCI). These institutions have the resources to manage the high demand for DES in treating patients with coronary artery disease, as they cater to both emergency and elective cases.
Specialty Clinics also play a significant role in the adoption of drug-eluting stents, particularly those focused on cardiology and interventional procedures. These clinics are specialized in providing high-quality, patient-centric care, with a focus on specific therapeutic areas like heart disease, vascular interventions, and post-operative care. Specialty clinics often serve as a cost-effective alternative to hospitals, offering a more personalized and focused environment for patients needing stent implants and other cardiovascular treatments. They may attract patients seeking minimally invasive procedures with shorter recovery times and lower healthcare costs.
The demand for drug-eluting stents in both hospitals and specialty clinics is driven by the rising prevalence of cardiovascular diseases, advancements in stent technology, and growing awareness of the benefits of DES over bare-metal stents. Hospitals typically handle more critical cases and perform surgeries involving drug-eluting stents as part of larger interventions, whereas specialty clinics focus on non-emergency, elective treatments and post-operative follow-ups. Together, these segments ensure a broad market for DES, allowing for the treatment of a wide patient population while addressing different levels of care, from emergency intervention to elective surgeries.
Global Drug Eluting Stents Market, Segmentation by Geography
In this report, the Global Drug Eluting Stents Market has been segmented by Geography into five regions; North America, Europe, Asia Pacific, Middle East and Africa and Latin America.
Global Drug Eluting Stents Market Share (%), by Geographical Region, 2024
North America's dominance in the drug eluting stent (DES) is attributed to several factors. The region boasts a well-established healthcare infrastructure and a high adoption rate of advanced medical technologies, contributing to the widespread use of DES. Moreover, the rising prevalence of cardiovascular diseases in North America has fueled the demand for effective treatments like DES, further driving market growth. Key players in the market, coupled with ongoing advancements in stent technology, also play a significant role in maintaining North America's market dominance. For instance, Abbott's FDA approval for its XIENCE Skypoint stent in June 2021, featuring a unique polymer coating, exemplifies the region's commitment to innovative solutions and contributes to its leadership position.
Conversely, the Asia-Pacific region is poised to experience the fastest compound annual growth rate (CAGR) of 9.3% over the forecast period. This rapid growth can be attributed to several factors, including the increasing prevalence of cardiovascular diseases in the region and advancements in healthcare infrastructure, particularly in rural areas. Improved access to quality medical care has facilitated the adoption of DES in the Asia-Pacific region. For example, the launch of Terumo Corporation's Ultimaster Tansei Drug-Eluting Stent in Japan in September 2018 underscores the continuous progress and opportunities in the Asia-Pacific market for innovative stent technologies. As healthcare facilities continue to evolve and expand across the region, the demand for DES is expected to rise, driving market growth in the coming years.
Market Trends
This report provides an in depth analysis of various factors that impact the dynamics of Global Drug Eluting Stents Market. These factors include; Market Drivers, Restraints and Opportunities Analysis.
Drivers, Restraints and Opportunity Analysis
Drivers
- Prevalence of Cardiovascular Diseases
- Technological Advancements in Stent Design
-
Growing Adoption of Minimally Invasive Procedures - The shift towards minimally invasive procedures has significantly influenced the demand for drug-eluting stents (DES). Minimally invasive percutaneous coronary intervention (PCI) procedures, which utilize DES implantation, have emerged as preferred alternatives to traditional open-heart surgeries for treating coronary artery disease. These procedures offer numerous advantages, including lower procedural risks, shorter recovery times, and improved patient outcomes compared to invasive surgical interventions. As patients and clinicians alike recognize the benefits of minimally invasive approaches, the demand for DES as a primary therapy for coronary artery disease has continued to surge, propelling market expansion.
The increasing adoption of minimally invasive techniques is driven by advancements in medical technology and techniques, which have enhanced the safety and efficacy of DES implantation procedures. Innovations in stent design, imaging technologies, and procedural techniques have contributed to improved patient outcomes and reduced complications associated with DES implantation. Consequently, the growing preference for minimally invasive procedures is expected to sustain the momentum in the DES market, driving further innovation and expansion in the coming years.
Restraints
- Regulatory Hurdles
- Competition from Alternative Therapies
-
Risk of Stent Thrombosis - Despite significant advancements in technology, the risk of stent thrombosis remains a persistent concern associated with Drug Eluting Stents (DES). Stent thrombosis occurs when a blood clot forms inside the stent, potentially leading to blockage of the coronary artery. While this complication is relatively rare, its consequences can be severe, including myocardial infarction (heart attack) or even death. This risk undermines the confidence of both physicians and patients in opting for DES as a treatment option for coronary artery disease.
Physicians must carefully weigh the benefits of DES, such as reducing restenosis rates compared to bare-metal stents, against the potential risks of stent thrombosis. Factors such as patient's medical history, comorbidities, and lifestyle choices are crucial considerations in the decision-making process. Additionally, advancements in stent design, drug coatings, and antiplatelet therapy regimens aim to mitigate the risk of stent thrombosis. However, the possibility of this complication persists, leading some physicians and patients to explore alternative treatments or preventive measures. Continued research and development efforts are essential to further minimize the occurrence of stent thrombosis and enhance the safety profile of DES, thereby bolstering confidence in its use among healthcare providers and patients alike.
Opportunities
- Emerging Markets
- Personalized Medicine
-
Expansion into Adjacent Therapies - Expanding the application of drug-eluting stents (DES) beyond coronary artery disease presents a promising avenue for growth in the medical device industry. Peripheral artery disease (PAD), characterized by narrowed arteries in the limbs, is a significant health concern affecting millions worldwide. Traditional treatments for PAD, such as angioplasty and stenting, often face challenges with restenosis, where the treated artery becomes narrowed again. By applying DES technology to treat PAD, companies can potentially mitigate restenosis rates and improve long-term outcomes for patients. This expansion into the PAD market not only addresses an unmet medical need but also opens up a lucrative growth opportunity for DES manufacturers, particularly as the prevalence of PAD continues to rise globally.
The exploration of DES applications in neurovascular interventions represents another avenue for expansion. Neurovascular diseases, including intracranial stenosis, pose serious risks such as stroke and cognitive impairment. While traditional treatment options like angioplasty and stenting exist, they often face challenges such as restenosis and thrombosis. By developing DES specifically tailored for neurovascular interventions, companies can potentially offer safer and more effective treatment options for patients. This diversification into neurovascular therapies not only expands the market reach of DES but also positions companies at the forefront of addressing critical neurological health issues. Overall, by exploring these adjacent therapies, companies can diversify their revenue streams, tap into new markets, and sustain long-term growth in the dynamic healthcare landscape.
Competitive Landscape Analysis
Key players in Global Drug Eluting Stents Market include
- Abbott Laboratories
- Boston Scientific Corporation
- Terumo Corporation
- Medtronic
- Biosensors International
- Cook Medical
- Envision Scientific
- Biotronik
- Lepu Medical
- Stentsys
In this report, the profile of each market player provides following information:
- Company Overview and Product Portfolio
- Key Developments
- Financial Overview
- Strategies
- Company SWOT Analysis
- Introduction
- Research Objectives and Assumptions
- Research Methodology
- Abbreviations
- Market Definition & Study Scope
- Executive Summary
- Market Snapshot, By Type
- Market Snapshot, By Drug Coating
- Market Snapshot, By Scaffold
- Market Snapshot, By Application
- Market Snapshot, By End User
- Market Snapshot, By Region
- Global Drug Eluting Stents Market Dynamics
- Drivers, Restraints and Opportunities
- Drivers
- Prevalence of Cardiovascular Diseases
- Technological Advancements in Stent Design
- Growing Adoption of Minimally Invasive Procedures
- Restraints
- Regulatory Hurdles
- Competition from Alternative Therapies
- Risk of Stent Thrombosis
- Opportunities
- Emerging Markets
- Personalized Medicine
- Expansion into Adjacent Therapies
- Drivers
- PEST Analysis
- Political Analysis
- Economic Analysis
- Social Analysis
- Technological Analysis
- Porter's Analysis
- Bargaining Power of Suppliers
- Bargaining Power of Buyers
- Threat of Substitutes
- Threat of New Entrants
- Competitive Rivalry
- Drivers, Restraints and Opportunities
- Market Segmentation
- Global Drug Eluting Stents Market, By Type, 2021 - 2031 (USD Million)
- Coronary Stenting
- Peripheral Stenting
- Global Drug Eluting Stents Market, By Drug Coating, 2021 - 2031 (USD Million)
- Polymer-Based Coatings
- Non - Biodegradable Polymers
- Biodegradable Polymers
- Polymer Free Coatings
- Micro Porous Surface
- Micro Structured Surface
- Slotted Tubular Surface
- Nanoporous Surface
- Polymer-Based Coatings
- Global Drug Eluting Stents Market, By Scaffold, 2021 - 2031 (USD Million)
- Cobalt-Chromium
- Platinum-Chromium
- Nitinol
- Others
- Global Drug Eluting Stents Market, By Application, 2021 - 2031 (USD Million)
- Coronary Artery Disease
- Peripheral Artery Disease
- Global Drug Eluting Stents Market, By End User, 2021 - 2031 (USD Million)
- Hospitals
- Specialty Clinics
- Global Drug Eluting Stents Market, By Geography, 2021 - 2031 (USD Million)
- North America
- United States
- Canada
- Europe
- Germany
- United Kingdom
- France
- Italy
- Spain
- Nordic
- Benelux
- Rest of Europe
- Asia Pacific
- Japan
- China
- India
- Australia & New Zealand
- South Korea
- ASEAN (Association of South East Asian Countries)
- Rest of Asia Pacific
- Middle East & Africa
- GCC
- Israel
- South Africa
- Rest of Middle East & Africa
- Latin America
- Brazil
- Mexico
- Argentina
- Rest of Latin America
- North America
- Global Drug Eluting Stents Market, By Type, 2021 - 2031 (USD Million)
- Competitive Landscape
- Company Profiles
- Abbott Laboratories
- Boston Scientific Corporation
- Terumo Corporation
- Medtronic
- Biosensors International
- Cook Medical
- Envision Scientific
- Biotronik
- Lepu Medical
- Stentsys
- Company Profiles
- Analyst Views
- Future Outlook of the Market